Summary
The Eastern Cooperative Oncology Group (ECOG) conducted a Phase II trial of Bruceantin in malignant melanoma. Twenty-two patients, thirteen without prior cytotoxic chemotherapy, were entered. All patients were evaluable for response and toxicity. Dose limiting toxicity was found to be hypotension during Bruceantin infusion. Other prominent side effects were nausea, vomiting, anorexia, fever, chills, and weakness. Only minor hematologic toxicity was encountered. Two partial responses, both in previously treated patients were observed (response rate — 9%). Bruceantin has only limited activity against malignant melanoma and is unlikely to contribute to systemic therapy of this disease, either as a single agent or in combinations of cytotoxic drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Bibliography
Bruceantin. Clinical Brochure. Investigational Drug Branch. Cancer Therapy Evaluation Program. Division of Cancer Treatment. NCI. Bethesda, MD. June, 1977
Kupchan SM, Britton RW, Ziegler MF, Sigel CW: Bruceantin, a new potent antileukemic simarouboilde from Brucea antidysenterica. J Org Chem 38:178, 1973
Liao LL, Kupchan SM, Horwitz SB: Mode of action of the antitumor compound, Bruceantin, an inhibitor of protein synthesis. Mol Pharm 12:167, 1976
Garnick MB, Blum RH, Canellos GP, et. al. Phase I trial of Bruceantin. Cancer Treat Rep 63:1929–1932, 1979
Bedikian AY, Valdivieso M, Bodey GP, et. al.: Initial clinical studies with Bruceantin. Cancer Treat Rep 63:1843–1847, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arseneau, J.C., Wolter, J.M., Kuperminc, M. et al. A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma. Invest New Drugs 1, 239–242 (1983). https://doi.org/10.1007/BF00208896
Issue Date:
DOI: https://doi.org/10.1007/BF00208896